Delivery platform to enable intracellular delivery of peptides

Peptide-based therapeutics have transformed medicine by offering high specificity, potent biological activity, and minimal off-target effects. They have demonstrated clinical success in cancer, metabolic diseases, and autoimmune disorders, yet their full potential remains severely constrained by poor intracellular delivery. Unlike small molecules, peptides do not readily cross cell membranes and are often sequestered in endosomes, leading to rapid degradation before reaching their intracellular targets. As a result, more than 90% of marketed peptide drugs are restricted to extracellular targets, limiting the therapeutic scope of peptide drugs. Overcoming this delivery barrier is a major unmet challenge in drug development, particularly for cancer, genetic diseases, and infectious diseases that require intracellular targeting.